LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

LLY

1,127.01

+3.92%↑

JNJ

231

-0.3%↓

ABBV

218.19

+1.61%↑

UNH

381.62

+0.04%↑

MRK

119.4

-1.18%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Atvērts

SektorsVeselības aprūpe

97.5 -0.02

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.02

Max

97.58

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.723 50.102
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.52% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	362M 19B
Iepriekšējā atvēršanas cena	97.52
Iepriekšējā slēgšanas cena	97.5

Ziņu noskaņojums

By Acuity

25%

75%

39 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. maijs 21:33 UTC

Peļņas

Correction to Salesforce 1Q Sales, Profit Rise Article

2026. g. 27. maijs 21:00 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026. g. 27. maijs 20:18 UTC

Peļņas

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026. g. 27. maijs 23:49 UTC

Tirgus saruna

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026. g. 27. maijs 23:39 UTC

Tirgus saruna

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026. g. 27. maijs 23:34 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 27. maijs 23:08 UTC

Tirgus saruna

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026. g. 27. maijs 22:21 UTC

Tirgus saruna

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026. g. 27. maijs 21:29 UTC

Karstas akcijas

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026. g. 27. maijs 21:08 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026. g. 27. maijs 21:02 UTC

Peļņas

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026. g. 27. maijs 20:59 UTC

Iegādes, apvienošanās, pārņemšana

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026. g. 27. maijs 20:55 UTC

Peļņas

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026. g. 27. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 27. maijs 20:48 UTC

Peļņas

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026. g. 27. maijs 20:45 UTC

Peļņas

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026. g. 27. maijs 20:34 UTC

Iegādes, apvienošanās, pārņemšana

Webster Financial Stockholders Approve Sale to Banco Santander

2026. g. 27. maijs 20:32 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026. g. 27. maijs 20:32 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026. g. 27. maijs 20:30 UTC

Peļņas

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026. g. 27. maijs 20:30 UTC

Iegādes, apvienošanās, pārņemšana

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026. g. 27. maijs 20:22 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:16 UTC

Peļņas

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026. g. 27. maijs 20:13 UTC

Peļņas

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026. g. 27. maijs 20:13 UTC

Peļņas

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026. g. 27. maijs 20:12 UTC

Peļņas

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.52% augšup

Prognoze 12 mēnešiem

Vidējais 108.29 USD 11.52%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

39 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation